Investors
A MESSAGE FROM OUR CEO
“We have excellent opportunities before us, and we remain focused on delivering patient, company and shareholder value.”
-
March 10, 2024 RegulatorySynAct Pharma announces outcomes of the independent audit of the 4-week RESOLVE P2a clinical trial in Rheumatoid Arthritis
-
February 27, 2024 RegulatoryMarina Bozilenko resigns from Board of Directors of SynAct Pharma
SynAct Pharma AB published its year-end report for 2023 on February 23 at 07.30 CET.
Conference call and online presentation: the same day at 15.00 CET.